{"entity":{"type":"insider","cik":"0001340097","url":"/insider/0001340097","json_url":"/insider/0001340097.json","name":"Invus Public Equities, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":70,"n_filings":38,"first":"2012-10-25","last":"2024-12-12","span_basis":"filed_date"},"name_variants":[{"name":"Invus Public Equities, L.P.","source":"filing","n_filings":38,"first_seen":"2012-10-25","last_seen":"2024-12-12"}],"transactions":[{"id":2181801,"accession":"0000950170-24-135847","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-135847","line_url":"/filing/0000950170-24-135847#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1600000.0,"shares_display":"1,600,000","price_per_share":41.65,"price_display":"41.65","price_state":"stated","total_value":66640000.0,"total_display":"66,640,000.00","total_whole":"66,640,000","shares_owned_after":9250005.0,"shares_owned_after_display":"9,250,005","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-10","filed_date":"2024-12-12","scope":"insider"},{"id":2958077,"accession":"0000950170-24-131539","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-131539","line_url":"/filing/0000950170-24-131539","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":409433.0,"shares_display":"409,433","price_per_share":38.48648981811432,"price_display":"38.49","price_state":"stated","total_value":15757638.9857,"total_display":"15,757,638.99","total_whole":"15,757,639","shares_owned_after":11051166.0,"shares_owned_after_display":"11,051,166","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-25","filed_date":"2024-11-27","scope":"insider","n_lines":5},{"id":2985829,"accession":"0000950170-24-094800","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-094800","line_url":"/filing/0000950170-24-094800#line-2","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":260873.0,"shares_display":"260,873","price_per_share":0.1917,"price_display":"0.19","price_state":"stated","total_value":50009.3541,"total_display":"50,009.35","total_whole":"50,009","shares_owned_after":6317565.0,"shares_owned_after_display":"6,317,565","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-08","filed_date":"2024-08-09","scope":"insider"},{"id":2985822,"accession":"0000950170-24-094800","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-094800","line_url":"/filing/0000950170-24-094800#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61488.0,"shares_display":"61,488","price_per_share":0.1821,"price_display":"0.18","price_state":"stated","total_value":11196.9648,"total_display":"11,196.96","total_whole":"11,197","shares_owned_after":6578438.0,"shares_owned_after_display":"6,578,438","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-07","filed_date":"2024-08-09","scope":"insider"},{"id":2205932,"accession":"0000950170-24-092864","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-092864","line_url":"/filing/0000950170-24-092864#line-2","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55732.0,"shares_display":"55,732","price_per_share":0.1828,"price_display":"0.18","price_state":"stated","total_value":10187.8096,"total_display":"10,187.81","total_whole":"10,188","shares_owned_after":6639926.0,"shares_owned_after_display":"6,639,926","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-06","filed_date":"2024-08-07","scope":"insider"},{"id":2205929,"accession":"0000950170-24-092864","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-092864","line_url":"/filing/0000950170-24-092864#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":164523.0,"shares_display":"164,523","price_per_share":0.1884,"price_display":"0.19","price_state":"stated","total_value":30996.1332,"total_display":"30,996.13","total_whole":"30,996","shares_owned_after":6695658.0,"shares_owned_after_display":"6,695,658","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-05","filed_date":"2024-08-07","scope":"insider"},{"id":2737316,"accession":"0000950170-24-090910","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-090910","line_url":"/filing/0000950170-24-090910#line-2","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":286200.0,"shares_display":"286,200","price_per_share":0.2004,"price_display":"0.20","price_state":"stated","total_value":57354.48,"total_display":"57,354.48","total_whole":"57,354","shares_owned_after":6860181.0,"shares_owned_after_display":"6,860,181","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-02","filed_date":"2024-08-05","scope":"insider"},{"id":2737310,"accession":"0000950170-24-090910","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-090910","line_url":"/filing/0000950170-24-090910#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63564.0,"shares_display":"63,564","price_per_share":0.2162,"price_display":"0.22","price_state":"stated","total_value":13742.5368,"total_display":"13,742.54","total_whole":"13,743","shares_owned_after":7146381.0,"shares_owned_after_display":"7,146,381","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-01","filed_date":"2024-08-05","scope":"insider"},{"id":2389003,"accession":"0000950170-24-088020","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-088020","line_url":"/filing/0000950170-24-088020#line-3","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":756835.0,"shares_display":"756,835","price_per_share":0.2209,"price_display":"0.22","price_state":"stated","total_value":167184.8515,"total_display":"167,184.85","total_whole":"167,185","shares_owned_after":7209945.0,"shares_owned_after_display":"7,209,945","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-30","filed_date":"2024-07-30","scope":"insider"},{"id":2388998,"accession":"0000950170-24-088020","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-088020","line_url":"/filing/0000950170-24-088020#line-2","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":363949.0,"shares_display":"363,949","price_per_share":0.2353,"price_display":"0.24","price_state":"stated","total_value":85637.1997,"total_display":"85,637.20","total_whole":"85,637","shares_owned_after":7966780.0,"shares_owned_after_display":"7,966,780","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-29","filed_date":"2024-07-30","scope":"insider"},{"id":2388995,"accession":"0000950170-24-088020","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-088020","line_url":"/filing/0000950170-24-088020#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":258335.0,"shares_display":"258,335","price_per_share":0.2417,"price_display":"0.24","price_state":"stated","total_value":62439.5695,"total_display":"62,439.57","total_whole":"62,440","shares_owned_after":8330729.0,"shares_owned_after_display":"8,330,729","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-26","filed_date":"2024-07-30","scope":"insider"},{"id":7888723,"accession":"0000950170-23-053600","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-23-053600","line_url":"/filing/0000950170-23-053600","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury","owner_display_name":"Artal Group S.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2199931.0,"shares_display":"2,199,931","price_per_share":6.857822204423684,"price_display":"6.86","price_state":"stated","total_value":15086735.66,"total_display":"15,086,735.66","total_whole":"15,086,736","shares_owned_after":11249288.0,"shares_owned_after_display":"11,249,288","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-12","filed_date":"2023-10-16","scope":"insider","n_lines":2},{"id":8569558,"accession":"0000899243-23-014464","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-014464","line_url":"/filing/0000899243-23-014464#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International S.C.A.; Invus Advisors, L.L.C.; Westend S.A.; Wittouck Amaury; Stichting Administratiekantoor Westend; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Invus, L.P.; Artal Group S.A.; Invus Public Equities, L.P.","owner_display_name":"Artal International S.C.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27775050.0,"shares_display":"27,775,050","price_per_share":2.6,"price_display":"2.60","price_state":"stated","total_value":72215130.0,"total_display":"72,215,130.00","total_whole":"72,215,130","shares_owned_after":78634381.0,"shares_owned_after_display":"78,634,381","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-05","filed_date":"2023-06-05","scope":"insider"},{"id":8351239,"accession":"0000899243-23-012043","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-012043","line_url":"/filing/0000899243-23-012043#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal Group S.A.; Stichting Administratiekantoor Westend; Wittouck Amaury; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Artal International Management S.A.; Westend S.A.; Artal International S.C.A.","owner_display_name":"Artal Group S.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31557.0,"shares_display":"31,557","price_per_share":6.4279,"price_display":"6.43","price_state":"stated","total_value":202845.2403,"total_display":"202,845.24","total_whole":"202,845","shares_owned_after":9059507.0,"shares_owned_after_display":"9,059,507","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-28","filed_date":"2023-05-02","scope":"insider"},{"id":7799633,"accession":"0000899243-23-006426","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-006426","line_url":"/filing/0000899243-23-006426#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal Group S.A.; Artal International Management S.A.; Stichting Administratiekantoor Westend; Westend S.A.; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Wittouck Amaury; Artal International S.C.A.","owner_display_name":"Artal Group S.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":1.7,"price_display":"1.70","price_state":"stated","total_value":170000.0,"total_display":"170,000.00","total_whole":"170,000","shares_owned_after":8589064.0,"shares_owned_after_display":"8,589,064","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-24","filed_date":"2023-02-28","scope":"insider"},{"id":8527929,"accession":"0000899243-23-006027","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-23-006027","line_url":"/filing/0000899243-23-006027#line-3","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International S.C.A.; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Wittouck Amaury; Stichting Administratiekantoor Westend; Artal Group S.A.; Westend S.A.; Invus Public Equities, L.P.","owner_display_name":"Artal International S.C.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":1.7538,"price_display":"1.75","price_state":"stated","total_value":350760.0,"total_display":"350,760.00","total_whole":"350,760","shares_owned_after":8489064.0,"shares_owned_after_display":"8,489,064","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-23","filed_date":"2023-02-23","scope":"insider"},{"id":8527924,"accession":"0000899243-23-006027","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-006027","line_url":"/filing/0000899243-23-006027#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International S.C.A.; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Wittouck Amaury; Stichting Administratiekantoor Westend; Artal Group S.A.; Westend S.A.; Invus Public Equities, L.P.","owner_display_name":"Artal International S.C.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":1.7933,"price_display":"1.79","price_state":"stated","total_value":268995.0,"total_display":"268,995.00","total_whole":"268,995","shares_owned_after":8289064.0,"shares_owned_after_display":"8,289,064","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-22","filed_date":"2023-02-23","scope":"insider"},{"id":8527918,"accession":"0000899243-23-006027","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-006027","line_url":"/filing/0000899243-23-006027#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International S.C.A.; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Wittouck Amaury; Stichting Administratiekantoor Westend; Artal Group S.A.; Westend S.A.; Invus Public Equities, L.P.","owner_display_name":"Artal International S.C.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":1.85,"price_display":"1.85","price_state":"stated","total_value":92500.0,"total_display":"92,500.00","total_whole":"92,500","shares_owned_after":8139064.0,"shares_owned_after_display":"8,139,064","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-21","filed_date":"2023-02-23","scope":"insider"},{"id":7939033,"accession":"0000899243-23-005502","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-23-005502","line_url":"/filing/0000899243-23-005502#line-3","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Wittouck Amaury; Stichting Administratiekantoor Westend; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities, L.P.; Westend S.A.; Artal Group S.A.; Invus Public Equities Advisors, LLC","owner_display_name":"Wittouck Amaury","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":1.705,"price_display":"1.70","price_state":"stated","total_value":341000.0,"total_display":"341,000.00","total_whole":"341,000","shares_owned_after":8089064.0,"shares_owned_after_display":"8,089,064","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-17","filed_date":"2023-02-17","scope":"insider"},{"id":7939031,"accession":"0000899243-23-005502","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-005502","line_url":"/filing/0000899243-23-005502#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Wittouck Amaury; Stichting Administratiekantoor Westend; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities, L.P.; Westend S.A.; Artal Group S.A.; Invus Public Equities Advisors, LLC","owner_display_name":"Wittouck Amaury","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":315266.0,"shares_display":"315,266","price_per_share":1.6847,"price_display":"1.68","price_state":"stated","total_value":531128.6302,"total_display":"531,128.63","total_whole":"531,129","shares_owned_after":7889064.0,"shares_owned_after_display":"7,889,064","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-16","filed_date":"2023-02-17","scope":"insider"},{"id":7939029,"accession":"0000899243-23-005502","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-005502","line_url":"/filing/0000899243-23-005502#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Wittouck Amaury; Stichting Administratiekantoor Westend; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities, L.P.; Westend S.A.; Artal Group S.A.; Invus Public Equities Advisors, LLC","owner_display_name":"Wittouck Amaury","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":2.1558,"price_display":"2.16","price_state":"stated","total_value":2155800.0,"total_display":"2,155,800.00","total_whole":"2,155,800","shares_owned_after":7573798.0,"shares_owned_after_display":"7,573,798","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-15","filed_date":"2023-02-17","scope":"insider"},{"id":8185387,"accession":"0000899243-23-004819","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-004819","line_url":"/filing/0000899243-23-004819#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Public Equities Advisors, LLC; Wittouck Amaury; Artal International S.C.A.; Artal International Management S.A.; Westend S.A.; Stichting Administratiekantoor Westend; Artal Group S.A.; Invus Public Equities, L.P.","owner_display_name":"Invus Public Equities Advisors, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11451.0,"shares_display":"11,451","price_per_share":3.2419,"price_display":"3.24","price_state":"stated","total_value":37122.9969,"total_display":"37,123.00","total_whole":"37,123","shares_owned_after":6573798.0,"shares_owned_after_display":"6,573,798","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-09","filed_date":"2023-02-13","scope":"insider"},{"id":8279028,"accession":"0000899243-23-001634","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-001634","line_url":"/filing/0000899243-23-001634#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Westend S.A.; Stichting Administratiekantoor Westend; Artal Group S.A.; Wittouck Amaury; Invus Public Equities Advisors, LLC; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities, L.P.","owner_display_name":"Westend S.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1094.0,"shares_display":"1,094","price_per_share":9.482,"price_display":"9.48","price_state":"stated","total_value":10373.308,"total_display":"10,373.31","total_whole":"10,373","shares_owned_after":9027950.0,"shares_owned_after_display":"9,027,950","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-09","filed_date":"2023-01-11","scope":"insider"},{"id":8135025,"accession":"0000899243-23-001307","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-001307","line_url":"/filing/0000899243-23-001307#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal Group S.A.; Stichting Administratiekantoor Westend; Wittouck Amaury; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Artal International Management S.A.; Westend S.A.; Artal International S.C.A.","owner_display_name":"Artal Group S.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":48774.0,"shares_display":"48,774","price_per_share":9.3306,"price_display":"9.33","price_state":"stated","total_value":455090.6844,"total_display":"455,090.68","total_whole":"455,091","shares_owned_after":9029044.0,"shares_owned_after_display":"9,029,044","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-05","filed_date":"2023-01-09","scope":"insider"},{"id":6533537,"accession":"0000899243-22-034318","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-034318","line_url":"/filing/0000899243-22-034318#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International Management S.A.; Westend S.A.; Invus Public Equities Advisors, LLC; Artal Group S.A.; Wittouck Amaury; Artal International S.C.A.; Stichting Administratiekantoor Westend; Invus Public Equities, L.P.","owner_display_name":"Artal International Management S.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":130265.0,"shares_display":"130,265","price_per_share":8.0404,"price_display":"8.04","price_state":"stated","total_value":1047382.706,"total_display":"1,047,382.71","total_whole":"1,047,383","shares_owned_after":8980270.0,"shares_owned_after_display":"8,980,270","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-25","filed_date":"2022-10-27","scope":"insider"},{"id":6691672,"accession":"0000899243-22-033263","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-033263","line_url":"/filing/0000899243-22-033263#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Public Equities, L.P.; Wittouck Amaury; Invus Public Equities Advisors, LLC; Artal Group S.A.; Artal International Management S.A.; Stichting Administratiekantoor Westend; Artal International S.C.A.; Westend S.A.","owner_display_name":"Invus Public Equities, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":66000.0,"shares_display":"66,000","price_per_share":7.8903,"price_display":"7.89","price_state":"stated","total_value":520759.8,"total_display":"520,759.80","total_whole":"520,760","shares_owned_after":8850005.0,"shares_owned_after_display":"8,850,005","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-04","filed_date":"2022-10-07","scope":"insider"},{"id":6691670,"accession":"0000899243-22-033263","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-033263","line_url":"/filing/0000899243-22-033263#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Public Equities, L.P.; Wittouck Amaury; Invus Public Equities Advisors, LLC; Artal Group S.A.; Artal International Management S.A.; Stichting Administratiekantoor Westend; Artal International S.C.A.; Westend S.A.","owner_display_name":"Invus Public Equities, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":33971.0,"shares_display":"33,971","price_per_share":7.0292,"price_display":"7.03","price_state":"stated","total_value":238788.9532,"total_display":"238,788.95","total_whole":"238,789","shares_owned_after":8784005.0,"shares_owned_after_display":"8,784,005","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-03","filed_date":"2022-10-07","scope":"insider"},{"id":6386319,"accession":"0000899243-22-028108","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-028108","line_url":"/filing/0000899243-22-028108#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International Management S.A.; Invus, L.P.; Stichting Administratiekantoor Westend; Invus Advisors, L.L.C.; Artal International S.C.A.; Wittouck Amaury; Invus Public Equities Advisors, LLC; Westend S.A.; Artal Group S.A.; Invus Public Equities, L.P.","owner_display_name":"Artal International Management S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2426070.0,"shares_display":"2,426,070","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":6065175.0,"total_display":"6,065,175.00","total_whole":"6,065,175","shares_owned_after":50859331.0,"shares_owned_after_display":"50,859,331","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-05","filed_date":"2022-08-09","scope":"insider"},{"id":6741599,"accession":"0000899243-22-027156","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-027156","line_url":"/filing/0000899243-22-027156#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Invus Public Equities Advisors, LLC; Westend S.A.; Invus, L.P.; Artal Group S.A.; Stichting Administratiekantoor Westend; Artal International S.C.A.; Artal International Management S.A.; Wittouck Amaury; Invus Public Equities, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16173800.0,"shares_display":"16,173,800","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":40434500.0,"total_display":"40,434,500.00","total_whole":"40,434,500","shares_owned_after":48433261.0,"shares_owned_after_display":"48,433,261","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-01","filed_date":"2022-08-01","scope":"insider"},{"id":5431584,"accession":"0000899243-21-031304","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-031304","line_url":"/filing/0000899243-21-031304#line-3","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Omega Therapeutics, Inc.","issuer_ticker":"OMGA","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Westend S.A.; Stichting Administratiekantoor Westend; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Wittouck Amaury; Artal International Management S.A.; Artal International S.C.A.; Artal Group S.A.; Artal Treasury Ltd","owner_display_name":"Westend S.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":875000.0,"shares_display":"875,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":14875000.0,"total_display":"14,875,000.00","total_whole":"14,875,000","shares_owned_after":2273530.0,"shares_owned_after_display":"2,273,530","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-03","filed_date":"2021-08-03","scope":"insider"},{"id":5431579,"accession":"0000899243-21-031304","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-031304","line_url":"/filing/0000899243-21-031304#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Omega Therapeutics, Inc.","issuer_ticker":"OMGA","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Westend S.A.; Stichting Administratiekantoor Westend; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Wittouck Amaury; Artal International Management S.A.; Artal International S.C.A.; Artal Group S.A.; Artal Treasury Ltd","owner_display_name":"Westend S.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":75000.0,"shares_display":"75,000","price_per_share":16.1379,"price_display":"16.14","price_state":"stated","total_value":1210342.5,"total_display":"1,210,342.50","total_whole":"1,210,343","shares_owned_after":75000.0,"shares_owned_after_display":"75,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-30","filed_date":"2021-08-03","scope":"insider"},{"id":4707537,"accession":"0000899243-21-004899","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-004899","line_url":"/filing/0000899243-21-004899#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Seer, Inc.","issuer_ticker":"SEER","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal Treasury Ltd; Artal International Management S.A.; Artal International S.C.A.; Artal Group S.A.; Invus Public Equities, L.P.; Wittouck Amaury; Invus Public Equities Advisors, LLC; Westend S.A.; Stichting Administratiekantoor Westend","owner_display_name":"Artal Treasury Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":252545.0,"shares_display":"252,545","price_per_share":64.153,"price_display":"64.15","price_state":"stated","total_value":16201519.385,"total_display":"16,201,519.38","total_whole":"16,201,519","shares_owned_after":5588366.0,"shares_owned_after_display":"5,588,366","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-01","filed_date":"2021-02-03","scope":"insider"},{"id":3204093,"accession":"0000899243-20-034268","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-034268","line_url":"/filing/0000899243-20-034268#line-1","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Artal Treasury Ltd; Invus Public Equities Advisors, LLC; Invus, L.P.; Invus Public Equities, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10937500.0,"shares_display":"10,937,500","price_per_share":3.2,"price_display":"3.20","price_state":"stated","total_value":35000000.0,"total_display":"35,000,000.00","total_whole":"35,000,000","shares_owned_after":32259461.0,"shares_owned_after_display":"32,259,461","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-16","filed_date":"2020-12-17","scope":"insider"},{"id":2117559,"accession":"0001628280-20-017346","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-20-017346","line_url":"/filing/0001628280-20-017346#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Seer, Inc.","issuer_ticker":"SEER","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal Treasury Ltd; Invus Public Equities, L.P.; Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Minne Pascal; Invus Public Equities Advisors, LLC; Westend S.A.; Stichting Administratiekantoor Westend","owner_display_name":"Artal Treasury Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":790000.0,"shares_display":"790,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":15010000.0,"total_display":"15,010,000.00","total_whole":"15,010,000","shares_owned_after":5840911.0,"shares_owned_after_display":"5,840,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-08","filed_date":"2020-12-10","scope":"insider"},{"id":2288270,"accession":"0000899243-20-030316","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-030316","line_url":"/filing/0000899243-20-030316#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"SQZ Biotechnologies Co","issuer_ticker":"SQZ","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International S.C.A.; Artal Group S.A.; Artal Treasury Ltd; Stichting Administratiekantoor Westend; Westend S.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Artal International Management S.A.; Minne Pascal","owner_display_name":"Artal International S.C.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":465000.0,"shares_display":"465,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":7440000.0,"total_display":"7,440,000.00","total_whole":"7,440,000","shares_owned_after":1606308.0,"shares_owned_after_display":"1,606,308","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-03","filed_date":"2020-11-03","scope":"insider"},{"id":2456226,"accession":"0000899243-20-017117","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-017117","line_url":"/filing/0000899243-20-017117#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Generation Bio Co.","issuer_ticker":"GBIO","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal Group S.A.; Artal Treasury Ltd; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Minne Pascal; Artal International Management S.A.; Stichting Administratiekantoor Westend; Westend S.A.","owner_display_name":"Artal Group S.A.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":800000.0,"shares_display":"800,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":15200000.0,"total_display":"15,200,000.00","total_whole":"15,200,000","shares_owned_after":2814191.0,"shares_owned_after_display":"2,814,191","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-16","filed_date":"2020-06-18","scope":"insider"},{"id":6646985,"accession":"0000899243-18-018727","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-018727","line_url":"/filing/0000899243-18-018727#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Westend S.A.; Invus, L.P.; Minne Pascal; Stichting Administratiekantoor Westend; Artal International S.C.A.; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Artal International Management S.A.; Invus Advisors, L.L.C.; Artal Group S.A.","owner_display_name":"Westend S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":57724.0,"shares_display":"57,724","price_per_share":12.4547,"price_display":"12.45","price_state":"stated","total_value":718935.1028,"total_display":"718,935.10","total_whole":"718,935","shares_owned_after":3516214.0,"shares_owned_after_display":"3,516,214","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-28","filed_date":"2018-06-29","scope":"insider"},{"id":6646981,"accession":"0000899243-18-018727","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-018727","line_url":"/filing/0000899243-18-018727#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Westend S.A.; Invus, L.P.; Minne Pascal; Stichting Administratiekantoor Westend; Artal International S.C.A.; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Artal International Management S.A.; Invus Advisors, L.L.C.; Artal Group S.A.","owner_display_name":"Westend S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":125114.0,"shares_display":"125,114","price_per_share":12.5361,"price_display":"12.54","price_state":"stated","total_value":1568441.6154,"total_display":"1,568,441.62","total_whole":"1,568,442","shares_owned_after":3458490.0,"shares_owned_after_display":"3,458,490","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-27","filed_date":"2018-06-29","scope":"insider"},{"id":6250830,"accession":"0000899243-18-018161","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-018161","line_url":"/filing/0000899243-18-018161#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Minne Pascal; Westend S.A.; Invus Advisors, L.L.C.; Invus Public Equities Advisors, LLC; Artal International Management S.A.; Invus Public Equities, L.P.; Invus, L.P.; Stichting Administratiekantoor Westend; Artal Group S.A.; Artal International S.C.A.","owner_display_name":"Minne Pascal","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":228264.0,"shares_display":"228,264","price_per_share":12.9459,"price_display":"12.95","price_state":"stated","total_value":2955082.9176,"total_display":"2,955,082.92","total_whole":"2,955,083","shares_owned_after":3333376.0,"shares_owned_after_display":"3,333,376","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-25","filed_date":"2018-06-26","scope":"insider"},{"id":6250827,"accession":"0000899243-18-018161","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-018161","line_url":"/filing/0000899243-18-018161#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Minne Pascal; Westend S.A.; Invus Advisors, L.L.C.; Invus Public Equities Advisors, LLC; Artal International Management S.A.; Invus Public Equities, L.P.; Invus, L.P.; Stichting Administratiekantoor Westend; Artal Group S.A.; Artal International S.C.A.","owner_display_name":"Minne Pascal","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25461.0,"shares_display":"25,461","price_per_share":13.3573,"price_display":"13.36","price_state":"stated","total_value":340090.2153,"total_display":"340,090.22","total_whole":"340,090","shares_owned_after":3105112.0,"shares_owned_after_display":"3,105,112","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-22","filed_date":"2018-06-26","scope":"insider"},{"id":6467164,"accession":"0000899243-18-017617","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-017617","line_url":"/filing/0000899243-18-017617#line-3","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Artal International S.C.A.; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Minne Pascal; Stichting Administratiekantoor Westend; Invus, L.P.; Artal Group S.A.; Westend S.A.; Invus Public Equities, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":51600.0,"shares_display":"51,600","price_per_share":13.2677,"price_display":"13.27","price_state":"stated","total_value":684613.32,"total_display":"684,613.32","total_whole":"684,613","shares_owned_after":3079651.0,"shares_owned_after_display":"3,079,651","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-21","filed_date":"2018-06-21","scope":"insider"},{"id":6467162,"accession":"0000899243-18-017617","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-017617","line_url":"/filing/0000899243-18-017617#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Artal International S.C.A.; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Minne Pascal; Stichting Administratiekantoor Westend; Invus, L.P.; Artal Group S.A.; Westend S.A.; Invus Public Equities, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12391.0,"shares_display":"12,391","price_per_share":13.2849,"price_display":"13.28","price_state":"stated","total_value":164613.1959,"total_display":"164,613.20","total_whole":"164,613","shares_owned_after":3028051.0,"shares_owned_after_display":"3,028,051","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-20","filed_date":"2018-06-21","scope":"insider"},{"id":6467157,"accession":"0000899243-18-017617","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-017617","line_url":"/filing/0000899243-18-017617#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Artal International S.C.A.; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Minne Pascal; Stichting Administratiekantoor Westend; Invus, L.P.; Artal Group S.A.; Westend S.A.; Invus Public Equities, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8982.0,"shares_display":"8,982","price_per_share":13.4512,"price_display":"13.45","price_state":"stated","total_value":120818.6784,"total_display":"120,818.68","total_whole":"120,819","shares_owned_after":3015660.0,"shares_owned_after_display":"3,015,660","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-19","filed_date":"2018-06-21","scope":"insider"},{"id":6217031,"accession":"0000899243-18-017071","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-017071","line_url":"/filing/0000899243-18-017071#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Stichting Administratiekantoor Westend; Minne Pascal; Artal International Management S.A.; Artal International S.C.A.; Invus Advisors, L.L.C.; Artal Group S.A.; Westend S.A.; Invus, L.P.; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC","owner_display_name":"Stichting Administratiekantoor Westend","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":36584.0,"shares_display":"36,584","price_per_share":13.0641,"price_display":"13.06","price_state":"stated","total_value":477937.0344,"total_display":"477,937.03","total_whole":"477,937","shares_owned_after":3006678.0,"shares_owned_after_display":"3,006,678","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-18","filed_date":"2018-06-18","scope":"insider"},{"id":6217026,"accession":"0000899243-18-017071","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-017071","line_url":"/filing/0000899243-18-017071#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Stichting Administratiekantoor Westend; Minne Pascal; Artal International Management S.A.; Artal International S.C.A.; Invus Advisors, L.L.C.; Artal Group S.A.; Westend S.A.; Invus, L.P.; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC","owner_display_name":"Stichting Administratiekantoor Westend","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9200.0,"shares_display":"9,200","price_per_share":12.6589,"price_display":"12.66","price_state":"stated","total_value":116461.88,"total_display":"116,461.88","total_whole":"116,462","shares_owned_after":2970094.0,"shares_owned_after_display":"2,970,094","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-14","filed_date":"2018-06-18","scope":"insider"}],"collapsed":true,"next_cursor":"2018-06-14|6217026","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001727196","name":"Scholar Rock Holding Corp","url":"/issuer/0001727196","role":"Ten percent owner","n_filings":9,"first_seen":"2018-05-31","last_seen":"2024-12-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001253689","name":"GLYCOMIMETICS INC","url":"/issuer/0001253689","role":"Ten percent owner","n_filings":8,"first_seen":"2023-02-13","last_seen":"2024-08-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001062822","name":"LEXICON PHARMACEUTICALS, INC.","url":"/issuer/0001062822","role":"Director, Ten percent owner","n_filings":16,"first_seen":"2012-10-25","last_seen":"2023-06-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001850838","name":"Omega Therapeutics, Inc.","url":"/issuer/0001850838","role":"Ten percent owner","n_filings":1,"first_seen":"2021-08-03","last_seen":"2021-08-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001726445","name":"Seer, Inc.","url":"/issuer/0001726445","role":"Ten percent owner","n_filings":2,"first_seen":"2020-12-10","last_seen":"2021-02-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001604477","name":"SQZ Biotechnologies Co","url":"/issuer/0001604477","role":"Ten percent owner","n_filings":1,"first_seen":"2020-11-03","last_seen":"2020-11-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001733294","name":"Generation Bio Co.","url":"/issuer/0001733294","role":"Ten percent owner","n_filings":1,"first_seen":"2020-06-18","last_seen":"2020-06-18"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001340097","retrieved_at":"2026-08-23T18:01:37+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}